ENDOMETRIAL HYPERPLASIA

This adverse event was reported 810 times

These drugs are most commonly taken by patients reporting ENDOMETRIAL HYPERPLASIA:

# Drug Count
0 LEVONORGESTREL 71
1 ADALIMUMAB 46
2 ESTRADIOL 38
3 TAMOXIFEN CITRATE 37
4 ANASTROZOLE 35
5 MEDROXYPROGESTERONE ACETATE 32
6 PROGESTERONE 30
7 LEVOTHYROXINE SODIUM 29
8 METFORMIN 29
9 METFORMIN ER 500 MG 29
See all common drugs associated with ENDOMETRIAL HYPERPLASIA

ENDOMETRIAL HYPERPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ESTRIOL,ESTRADIOL 1 0.2000
1 FRANKINCENSE 2 0.0328
2 TOREMIFENE CITRATE 9 0.0209
3 DROSPIRENONE AND ESTRADIOL 4 0.0074
4 TAMOXIFEN CITRATE 37 0.0064
5 CONJUGATED ESTROGENS/BAZEDOXIFENE 6 0.0064
6 TOLMETIN SODIUM 1 0.0059
7 MIFEPRISTONE 26 0.0054
8 ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE 2 0.0054
9 ESTERIFIED ESTROGENS, METHYLTESTOSTERONE 2 0.0054
See all drugs enriched for association with ENDOMETRIAL HYPERPLASIA

ENDOMETRIAL HYPERPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Progestin Antagonist [EPC] 26 0.0054
1 Estrogen Agonist/Antagonist [EPC] 5 0.0019
2 Progesterone [EPC] 30 0.0013
3 gamma-Aminobutyric Acid A Receptor Agonist [EPC] 2 0.0012
4 Provitamin D2 Compound [EPC] 32 0.0011
5 Ergot Derivative [EPC] 4 0.0008
6 Pyrethroid [EPC] 1 0.0006
7 Androgen [EPC] 15 0.0005
8 Blood Viscosity Reducer [EPC] 2 0.0005
9 Estrogen [EPC] 85 0.0005
See all drug classes enriched for association with ENDOMETRIAL HYPERPLASIA